Entos Pharmaceuticals Inc. (Entos), viral olmayan, yeniden dozlanabilir Fusogenix PLV da\u011f\u0131t\u0131m teknolojisini kullanarak genetik terapiler \u00fcreten bir biyoteknoloji \u015firketidir. CureDuchenne Ventures, Entos'a ilk olarak $1 milyon yat\u0131r\u0131m yapt\u0131\u011f\u0131n\u0131 duyurdu. Duchenne kas distrofisini (DMD) tedavi etmek i\u00e7in Entos, bu finansman\u0131 tam uzunlukta distrofin sa\u011flayan kas hedefli bir terapi geli\u015ftirmek i\u00e7in kullanacak.<\/p>\n\n\n\n
CureDuchenne'nin kurucusu ve CEO'su Debra Miller, "Entos Pharmaceuticals teknolojisinin potansiyelinden \u00e7ok heyecan duyuyoruz ve mevcut AAV tabanl\u0131 yakla\u015f\u0131mlar\u0131n s\u0131n\u0131rlamalar\u0131n\u0131 a\u015fan bir gen terapisi aray\u0131\u015f\u0131nda Entos ile i\u015f birli\u011fi yapmay\u0131 d\u00f6rt g\u00f6zle bekliyoruz. Bu terapi, \u00f6nceden ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 olan ki\u015fileri d\u0131\u015flamayacak, yeniden dozlamaya izin verecek ve en \u00f6nemlisi, t\u00fcm gerekli kas dokular\u0131na tam uzunlukta distrofin iletecek" dedi. Fusogenix PLV<\/a> \u2013<\/p>\n\n\n\n \u201cCureDuchenne, uzun zamand\u0131r yenilik\u00e7i terap\u00f6tik yakla\u015f\u0131mlar\u0131n finansman\u0131nda lider konumdad\u0131r ve bu yat\u0131r\u0131m, Duchenne i\u00e7in d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc tedavilere do\u011fru ilerlemeyi h\u0131zland\u0131rmak i\u00e7in giri\u015fim hay\u0131rseverli\u011fini kullanmaya devam etti\u011fimizi vurgulamaktad\u0131r. Ba\u011f\u0131\u015f\u00e7\u0131lar\u0131m\u0131za ve Duchenne toplulu\u011funa i\u00e7ten \u015f\u00fckranlar\u0131m\u0131z\u0131 sunuyoruz; deste\u011finiz bu yat\u0131r\u0131m\u0131 m\u00fcmk\u00fcn k\u0131ld\u0131 ve bir tedaviye do\u011fru ilerlemeyi s\u00fcrd\u00fcrmeye devam ediyor.\u201d<\/p>\n\n\n\n Fusogenix PLV da\u011f\u0131t\u0131m platformu, v\u00fccuttaki h\u00fccrelere ve dokulara terap\u00f6tik n\u00fckleik asit y\u00fcklerinin f\u00fczyonunu ve h\u00fccre i\u00e7i da\u011f\u0131t\u0131m\u0131n\u0131 sa\u011flamak i\u00e7in tescilli f\u00fczojenik FAST proteinlerimizle form\u00fcle edilmi\u015ftir; b\u00f6ylece bu \u00e7ok ihtiya\u00e7 duyulan tedaviler ger\u00e7e\u011fe d\u00f6n\u00fc\u015f\u00fcr.<\/p>\n\n\n\n \u201cFusogenix PLV platformu, distrofin gibi tam uzunluktaki i\u015flevsel genlerin v\u00fccuttaki kas h\u00fccrelerine g\u00fcvenli, etkili ve tekrarlanabilir bir \u015fekilde iletilmesini sa\u011flar. Fusogenix PLV tabanl\u0131 tedavilerin gerekti\u011finde birden fazla kez verilebilece\u011fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, bu ger\u00e7ek bir oyun de\u011fi\u015ftirici olabilir,\u201d dedi Entos Pharmaceuticals CEO'su John Lewis. \u201cBu yakla\u015f\u0131m\u0131n Duchenne kas distrofisi olan ki\u015filer ve aileleri i\u00e7in ger\u00e7ek bir fark yarataca\u011f\u0131n\u0131 umuyoruz.\u201d<\/p>","protected":false},"excerpt":{"rendered":" Entos Pharmaceuticals Inc. (Entos) is a biotech business that creates genetic therapies using its non-viral, redosable Fusogenix PLV delivery technology. CureDuchenne Ventures announced an initial $1 million investment in Entos. In order to cure Duchenne muscular dystrophy (DMD), Entos will use this financing to develop a muscle-targeting therapy that delivers full-length dystrophin. CureDuchenne Ventures Invests […]<\/p>\n","protected":false},"author":1,"featured_media":3873,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[369,359,370,61],"class_list":["post-3872","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-entos-pharmaceuticals","tag-full-length-dystrophin","tag-fusogenix-plv","tag-gene-therapy"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3872"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3872\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3873"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Fusogenix PLV nedir<\/h2>\n\n\n\n